The multivariate models included all factors associated with a given outcome at the. 10 level of significance. Multivariate P values for a variable were based on adjustment for all other variables in the model. All P values were derived from likelihood ratio statistics and were 2 sided. Statistical analysis was performed using SAS version 8. Expected population mortality rates were based on sex specific 2001 US life table data from the National Center for Health Statistics. The median age of patients was 64. 1 years. ABLE shows demographic, disease, and transplant characteristics for all patients, as stratified by age groups. Older patients more frequently underwent transplantation for acute leukemia and myelodysplastic syndromes /myeloproliferative diseases and less frequently for multiple myeloma/lymphoma.

Older patient age was associated with older donor age, shorter times between diagnosis and HCT, and fewer preceding chemotherapy regimens or prior HCT. Differences between age groups did not reach statistical PH-797804 significance for other variables. Median pretransplant KPS percentage was 90%, while the median HCT CI score was 2. As of June 23, 2010, 133 of the 372 patients were alive, with a median follow up of 55 months. By 120 days, cumulative incidences of acute GVHDwere52% for grades II IV and 13% for grades III IV. The cumulative incidence of extensive chronicGVHDat 2 years was 42%. Cumulative incidences of nonrelapse mortality were 7% at 100 days after HCT, 20% at 1 year, and 27% at 5 years. Relapse rates were 33% at 1 year after HCT and 41% at 5 years.

Five year rates of overall survival and progression free survival were 35% and 32%, respectively. Among 3 year survivors, the subsequent 5 year survival was 61%, compared with 88% expected for an age and sexmatched general population. Cell Cycle Overall, disease progression or relapse has been the most common cause of death. Nonrelapse deaths occurred among 104 patients, mainly due to infections, GVHD, and multiorgan failure. In aggregate, the time point order of causes of death, per median onset, was organ failure followed by GVHD, infections, cerebrovascular accidents, and second cancers. Cumulative incidences for nonrelapse mortality at 5 years were comparable among the 3 age groups. The hazard ratio for nonrelapse mortality per 5 years of age was 1. 04. Likewise, the 5 year rates of relapse were similar.

The hazard ratio for relapse per 5 years of age was 1. 19. Complete remission rates at 5 years among the 3 age groups were 40%, 40%, and 63%, respectively. The hazard ratio for remission per 5 years of age was 1. 30. Five year rates of overall survival were 38% Dasatinib for patients aged 60 through 64, 33% for those aged 65 through 69, and 25% for those 70 years or older. The hazard ratio for mortality per 5 years of age was 1. 16. The 5 year rates of progression free survival were 34%, 29%, and 27%, respectively. The hazard ratio for progression free survival per 5 years of age was 1. 13. At 120 days, the 3 age groups had comparable incidences of grades II IV acute GVHD or grades III IV acute GVHD. The hazard ratio for grade II IV acute GVHD per 5 years of age was 0.

86 and for grade III IVGVHD was 0. 70. Rates of chronic GVHD at 2 years were also comparable. The hazard ratio for extensive chronic GVHD per 5 years of age was 1. 14. Grades III and IV organ toxicities within the first 100 days were comparable among the 3 age groups. The hazard ratio for grade III toxicity per 5 years of age was 1. 12, and for grade IV toxicity was Dasatinib 1. 03. Rates of bacterial infection episodes per 100 patient days of risk within the first 100 days varied among the 3 age groups. The rate ratio for bacterial infection per 5 years of age was 1. 19. The rates of viral infection episodes were similar among the 3 age groups, as were rates of fungal infection episodes. The rate ratio for viral infection per 5 years of age was 1. 00 and for fungal infection was 1. 05.

Overall, 54% of patients aged 60 through 64, 36% of those aged 65 through 69, and 55% of those 70 years or older were either never hospitalized or hospitalized only overnight HSP for unrelated donor stem cell infusion within the first 100 days after HCT. Median percentages of CD33 donor chimerism at day 28 were 98% for patients aged 60 through 64, 99% for those aged 65 through 69, and 97% for those 70 years or older, and all reached 100% at day 180. Median percentages of CD3 donor chimerism at day 28 were 82%, 84%, and 73%, respectively, and all reached 99% at day 180. Rates of graft rejection were similar among patients in the 3 age groups. The hazard ratio for rejection per 5 years of age was 0. 96.

Overall, at 5 years after HCT, an estimated 14% of patients continued to require immunosuppressive medications, while 21% of patients had all immunosuppressive medications discontin ued, in a median of 30 months, indicating resolution of chronic GVHD. Among the 158 patients who developed extensive chronic GVHD, the rates of discontinuation of immunosuppressive drugs within 5 years after onset of chronicGVHDwere 43% for patients aged 60 through 64 vs 33% for those aged 65 through 69 vs 20% for those 70 or older. The hazard ratio for discontinuation of immunosuppression per 5 years of age was 0. 80. Among 133 patients alive at last contact, 115 were assessed by physicians for physical function using the KPS, with a median value of 90% for patients both with or without chronic GVHD. Multiple risk factors were analyzed for their associations with nonrelapse mortality, relapse, overall survival, and progression free survival using univariate analyses.

Patient age, patient/donor sex combinations, CD34_ cell dose, CD3 cell dose, pre HCT KPS percentages, number of preceding chemotherapy regimens, prior radiation, and totalbody irradiation dose were not significantly associated with any of the 4 outcomes at the. 10 level of significance. The remaining factors that were associated with each outcome in univariate analyses at the. 10 level of significance were entered in multivariate analyses.

Related posts: